HIGHLIGHTS
- who: Toshiyuki Nishikido from the Efficacy and safety in EU have published the article: Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease, in the Journal: (JOURNAL)
- what: This global study is designed to assess whether inclisiran reduces the risk of 3-point-major adverse cardiovascular events, defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke.
- future: The ORION-3 trial (NCT03060577) a phase 2 openlabel extension of the ORION-1 trial assessed the longterm efficacy and safety of inclisiran for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.